Robuta

https://www.technologynetworks.com/genomics/news/silence-therapeutics-announces-successful-opposition-of-glover-patent-209485
Silence announces the successful opposition of a fundamental Alnylam European patent resulting in the patent being revoked in its entirety.
silence therapeuticsannouncessuccessfuloppositionglover
https://www.benzinga.com/24/11/42073596/analyst-sees-competitive-concerns-for-silence-therapeutics-zerlasiran
Silence Therapeutics' Phase 2 data shows zerlasiran achieves over 80% Lp(a) reduction in ASCVD patients but faces dosing frequency challenges.
silence therapeuticszerlasirancompetitiveconcernsanalyst
https://www.webull.com/quote/otcpk-slncf
Webull offers Silence Therapeutics Plc (SLNCF) historical stock prices, in-depth market analysis, OTCPK: SLNCF real-time stock quote data, in-depth charts.
silence therapeutics plcstock quoteswebull
https://www.benzinga.com/insights/analyst-ratings/24/08/40414953/analyst-expectations-for-silence-therapeuticss-future
silence therapeuticsanalystexpectationsfuturenasdaq
https://www.fool.com/earnings/call-transcripts/2021/05/03/silence-therapeutics-plc-american-depository-share/
SLN earnings call for the period ending December 31, 2020.
silence therapeutics plcearnings call transcriptsln